Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Liza Leventhal"'
Autor:
Dávid Nagy, Lauren Herl Martens, Liza Leventhal, Angela Chen, Craig Kelley, Milan Stoiljkovic, Mihály Hajós
Publikováno v:
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-7 (2019)
Abstract Background Loss-of-function mutations in the progranulin gene cause frontotemporal dementia, a genetic, heterogeneous neurodegenerative disorder. Progranulin deficiency leads to extensive neuronal loss in the frontal and temporal lobes, alte
Externí odkaz:
https://doaj.org/article/f3a858b8d919446db06352066062a5ab
Autor:
Liza Leventhal, Milan Stoiljkovic, Dávid Nagy, Lauren Herl Martens, Mihály Hajós, Craig Kelley, Angela Chen
Publikováno v:
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-7 (2019)
Alzheimer's Research & Therapy
Alzheimer's Research & Therapy
Background Loss-of-function mutations in the progranulin gene cause frontotemporal dementia, a genetic, heterogeneous neurodegenerative disorder. Progranulin deficiency leads to extensive neuronal loss in the frontal and temporal lobes, altered synap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdfdec52caca087b9a73dbcc95d3ffa2
http://link.springer.com/article/10.1186/s13195-019-0540-x
http://link.springer.com/article/10.1186/s13195-019-0540-x
Autor:
Gunasingh J. Masilamoni, Christopher G. Sinon, Brik A. Kochoian, Arun Singh, Andrew J. McRiner, Liza Leventhal, Stella M. Papa
Publikováno v:
Neuropharmacology. 212:109060
Phosphodiesterase 9 (PDE9) degrades selectively the second messenger cGMP, which is an important molecule of dopamine signaling pathways in striatal projection neurons (SPNs). In this study, we assessed the effects of a selective PDE9 inhibitor (PDE9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4ed8cf7cf405395901a8e008d8a5b1b
https://doi.org/10.1016/j.neuropharm.2022.109060
https://doi.org/10.1016/j.neuropharm.2022.109060
Autor:
Dorothy G. Flood, Jean-Sebastien Walczak, Gerhard Koenig, Matthew Townsend, Ross Jeggo, Holger Patzke, Liza Leventhal, Andrew D. Whyment, Marco van den Top
Publikováno v:
Journal of Neurophysiology. 116:2663-2675
Agonists of the α7-nicotinic acetylcholine receptor (α7-nAChR) have entered clinical trials as procognitive agents for treating schizophrenia and Alzheimer's disease. The most advanced compounds are orthosteric agonists, which occupy the ligand bin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b62ad09154a5804f30e085f649be2e1
https://doi.org/10.1152/jn.00243.2016
https://doi.org/10.1152/jn.00243.2016
Autor:
Gunasingh J. Masilamoni, Stella M. Papa, Liza Leventhal, Subramanian Uthayathas, Gerhard Koenig
Publikováno v:
Neuropharmacology. 110:449-457
Schizophrenia symptoms are associated with alterations in basal ganglia-cortical networks that include the cyclic nucleotides (cAMP/cGMP) signaling pathways. Phosphodiesterase 10A (PDE10A) inhibitors have been considered as therapeutic agents for sch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19264c1aae08e224ece19ef3afc207ef
https://doi.org/10.1016/j.neuropharm.2016.08.012
https://doi.org/10.1016/j.neuropharm.2016.08.012
Autor:
Dávid Nagy, Milan Stoiljkovic, Gerhard Koenig, Mihály Hajós, Gábor Patrick Hajós, Craig Kelley, Liza Leventhal
Publikováno v:
Neurobiology of Aging. 45:161-168
Amyloid-β (Aβ) peptide overproduction is one of the pathomechanisms contributing to Alzheimer's disease (AD). Agonists of α7 nicotinic acetylcholine receptors (α7 nAChRs) are under development as symptomatic treatments for AD, and clinical findin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::408113c7f148dab6c19290f459048a12
https://doi.org/10.1016/j.neurobiolaging.2016.05.021
https://doi.org/10.1016/j.neurobiolaging.2016.05.021
Autor:
Mihály Hajós, Zhiming Tu, Ting Chen, Matthew Townsend, Milan Stoiljkovic, Dorothy G. Flood, Hilliary Hodgdon, Daniel Bertrand, Liza Leventhal, Dávid Nagy, Gerhard Koenig, Angela Chen, Raymond S. Hurst, Timothy M. Piser, Cuyue Tang, Rachelle Driscoll
Publikováno v:
Biochemical Pharmacology. 97:576-589
Pharmacological activation of α7 nicotinic acetylcholine receptors (α7 nAChRs) may improve cognition in schizophrenia and Alzheimer's disease. The present studies describe an integrated pharmacological analysis of the effects of FRM-17874, an analo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::945e50f33ae5780980b6ee6800eca3ee
https://doi.org/10.1016/j.bcp.2015.07.006
https://doi.org/10.1016/j.bcp.2015.07.006
Publikováno v:
Neuropharmacology. 110
Neural α7 nicotinic acetylcholine receptors (α7 nAChRs) emerged as a potential pharmacologic target for treating cognitive deficits in schizophrenia and Alzheimer's disease. Experiments modeling these dysfunctions, as well as clinical evidence, dem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c481ff2653ea3603eaa5aea50271d8d3
https://pubmed.ncbi.nlm.nih.gov/27422408
https://pubmed.ncbi.nlm.nih.gov/27422408
Autor:
G H Johnston, Eugene John Trybulski, John C. L. Erve, Brian W. Strassle, A. Adedoyin, Jeffrey D. Kennedy, James E. Harrison, Claudine Pulicicchio, Michael J. Piesla, Peimin Lu, Kathryn E. Rogers, Puwen Zhang, Brian J. Platt, Terri Cummons, Garth T. Whiteside, Liza Leventhal, Chad E. Beyer, Zoë A. Hughes, Darlene C. Deecher, L Manzino, Lilly Mark, Jason M. Dwyer
Publikováno v:
British Journal of Pharmacology. 160:1105-1118
Background and purpose: Antidepressants, which raise the CNS concentrations of 5-HT and noradrenaline, are frequently used in the treatment of chronic pain; however, it is not known if increasing CNS noradrenaline levels alone is sufficient for effic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4f60e6b8a1f1b1cc97f891a5bd642c1
https://doi.org/10.1111/j.1476-5381.2010.00690.x
https://doi.org/10.1111/j.1476-5381.2010.00690.x
Autor:
Stephen Todd Cohn, Garth T. Whiteside, Darlene C. Deecher, Grace H. Johnston, Paige Erin Mahaney, Valerie Smith, Scott Cosmi, Puwen Zhang, Elizabeth Koury, Eugene John Trybulski, Kim Callain Younghee, Jenifer A. Bray, Liza Leventhal, An T. Vu, Jeffrey D. Kennedy, James E. Harrison
Publikováno v:
Journal of Medicinal Chemistry. 53:2051-2062
Efforts to identify new selective and potent norepinephrine reuptake inhibitors (NRIs) for multiple indications by structural modification of the previous 3-(arylamino)-3-phenylpropan-2-olamine scaffold led to the discovery of a novel series of 1-(in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19d38a82f4c68b40baf4a429e77967f7
https://doi.org/10.1021/jm901559e
https://doi.org/10.1021/jm901559e